stoxline Quote Chart Rank Option Currency Glossary
  
Adagio Therapeutics, Inc. (ADGI)
4.64  0.04 (0.87%)    09-13 00:00
Open: 4.62
High: 4.74
Volume: 534,999
  
Pre. Close: 4.6
Low: 4.4
Market Cap: 506(M)
Technical analysis
2022-11-18 4:18:23 PM
Short term     
Mid term     
Targets 6-month :  5.53 1-year :  6.46
Resists First :  4.73 Second :  5.53
Pivot price 4.59
Supports First :  3.74 Second :  3.13
MAs MA(5) :  4.63 MA(20) :  4.39
MA(100) :  3.97 MA(250) :  6.23
MACD MACD :  0.2 Signal :  0.2
%K %D K(14,3) :  89.7 D(3) :  90.1
RSI RSI(14): 70.7
52-week High :  78.81 Low :  2.41
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ADGI ] has closed below upper band by 43.3%. Bollinger Bands are 41.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.74 - 4.77 4.77 - 4.79
Low: 4.35 - 4.37 4.37 - 4.39
Close: 4.6 - 4.64 4.64 - 4.68
Company Description

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Headline News

Mon, 12 Sep 2022
Adagio Therapeutics changes name to Invivyd, generates COVID-19 antibodies - Seeking Alpha

Mon, 12 Sep 2022
Adagio Therapeutics Announces Corporate Name Change to Invivyd - Yahoo Finance

Fri, 29 Jul 2022
(ADGI) News: Did You Lose Money on Your Adagio Therapeutics - GlobeNewswire

Wed, 23 Mar 2022
2 Net Current Asset Value Stocks to Consider - Yahoo Finance

Fri, 21 Jan 2022
Adagio Therapeutics Inc. (NASDAQ: ADGI) Announces That ADG20 Produced A Neutralizing Response Against The Omicron Variant - BP Journal

Wed, 15 Dec 2021
Top 5 IPOs of 2021 - Investopedia

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 111 (M)
Shares Float 48 (M)
Held by Insiders 32.5 (%)
Held by Institutions 67.1 (%)
Shares Short 3,920 (K)
Shares Short P.Month 4,380 (K)
Stock Financials
EPS -14.74
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.69
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -220 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.32
PEG Ratio 0
Price to Book value 0.81
Price to Sales 0
Price to Cash Flow -2.35
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android